All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial
DiscussionOverall survival rate is the primary endpoint. Secondary endpoints are time to progression according to the modified response evaluation criteria in solid tumors (mRECIST) criteria, acute and chronic adverse events, and quality of life.Trial registrationChinese Clinical Trial Registry,ChiCTR-IIR-17012916. Registered on 9 October 2017.
Source: Trials - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Eloxatin | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Palliative | Research | Study